Our experienced scientists and researchers customize and implement Goal Attainment Scaling (GAS) research across various disease areas from Alzheimer disease to oncology to hemophilia. We are pioneers in the standardized implementation of GAS in clinical development using goal inventories, extensive training, specialized software for GAS data capture, and cutting-edge methods to ensure rigorous goal quality. We are the partner of choice for big pharma, biotech, and other CROs to generate personalized evidence as demonstrated by our extensive publication record.
Ardea Outcomes is proud to be a co-investigator on the Inchstone Project focused on the development of outcome measures for the severe developmental and epileptic encephalopathies (DEEs). In collaboration with consumers, industry partners, clinicians, and academics, we are adapting existing outcome measures for individuals with DEEs who have severe functional and cognitive impairments and whose progress cannot be meaningfully captured with existing, standardized outcomes. As part of this cutting-edge project, we piloted Goal Attainment Scaling (GAS) in the SNC2A-associated Neurodevelopmental Disorders.
Explore our GAS publications which showcase our work in the field and the ways we can support personalized evidence generation throughout the clinical development life cycle.
Incorporating the patient voice and patient engagement in GOAL‐Hēm: Advancing patient‐centric hemophilia care.
In collaboration with research partners, Ardea Outcomes developed Goal-Hēm, a novel, hemophilia-specific patient-reported outcome tool developed to incorporate patient voice when developing Goal Attainment Scaling for Hemophilia. In addition to updating the language for multiple goals and descriptors, we found that participants were enthusiastic about patient-centric language, were empowered through goal-setting, and recognized that GOAL-Hēm could measure clinically meaningful change.
